Antiepileptic drugs (AEDs) protect against seizures through interactions with a variety of cellular targets. By affecting the functional activity of these targets, AEDs suppress abnormal hypersynchronous activity in brain circuits, leading to protection against seizures. The actions on these targets can be categorized into four broad groups: (i) modulation of voltage-gated ion channels, including sodium, calcium, and potassium channels; (ii) enhancement of GABA inhibition through effects on GABA<sub>Δ</sub> receptors, the GAT-1 GABA transporter, or GABA transaminase; (iii) direct modulation of synaptic release through effects on components of the release machinery, including SV2A and α2δ; and (iv) inhibition of synaptic excitation mediated by ionotropic glutamate receptors, including AMPA receptors (Table 43.1). The ultimate effects of these interactions are to modify the bursting properties of neurons and to reduce synchronization in localized neuronal ensembles. In addition, AEDs inhibit the spread of abnormal firing to distant sites. Some seizures, including typical generalized absence seizures, result from thalamocortical synchronization. AEDs effective in these seizure types interfere with the rhythm-generating mechanisms that underlie synchronized activity in the thalamocortical circuit. In this chapter, we consider each of the targets and discuss how AEDs affect the activity of these targets.

Many AED targets are ion channels, most notably voltage-gated sodium and potassium channels and GABA<sub>Δ</sub> receptors. It is interesting to note that certain idiopathic epilepsy syndromes are believed to be the result of mutations in these same ion channels (see Chapter 4).

**VOLTAGE-GATED ION CHANNELS**

**Voltage-Gated Sodium Channels**

Voltage-gated sodium channels play an essential role in the initiation and propagation of action potentials in neurons. Neuronal depolarizations by a few millivolts, ordinarily as a result of synaptic activation of glutamate receptors (mainly AMPA receptors), activate sodium channels, causing opening of the channels and influx of sodium. The channels then inactivate within milliseconds. Influx of sodium ions during the brief time that sodium channels are open generates the depolarizing component of the action potential. Although the bulk of sodium channels inactivate, about 1% of the sodium current is noninactivating resulting in a small persistent sodium current (I<sub>Na</sub><sup>P</sup>), which is carried by the same channels as the fast transient current. I<sub>Na</sub><sup>P</sup> facilitates epileptic burst firing by reducing the threshold for action potential generation, sustaining repetitive firing, and enhancing depolarizing synaptic currents (1).

Some AEDs, most notably phenytoin, inhibit I<sub>Na</sub><sup>P</sup>, which is believed to contribute to their efficacy (2).

Voltage-gated sodium channels are multimeric protein complexes, composed of a large α subunit that forms four subunit-like homologous domains (designated I to IV) and one or more smaller β subunits (3). The ion-conducting pore is contained within the α subunit, as are the elements of the channel that mediate its fundamental physiologic properties including rapid inactivation. There are nine voltage-gated sodium channels, designated Na<sub>1.1</sub> to Na<sub>1.9</sub>. Na<sub>1.2</sub> is the predominant form in brain neurons, but Na<sub>1.1</sub> and Na<sub>1.6</sub> are also expressed in the brain. Mutations in each of these channels have been associated with various genetic epilepsies (4).

AEDs that protect against seizures through an interaction with voltage-gated sodium channels are commonly referred to as “sodium channel blockers.” They are among the most frequently used drugs in the treatment of focal and primary generalized tonic–clonic seizures and include phenytoin, carbamazepine, lamotrigine, oxcarbazepine (as well as its active metabolitelicarbazepine), and lacosamide. AEDs that interact with voltage-gated sodium channels exhibit a characteristic “use-dependent” blocking action so that they inhibit high-frequency trains of action potentials much more potently than they inhibit individual action potentials or firing at low frequencies. Because they also exhibit a “voltage dependence” to their blocking action, sodium channel–blocking AEDs are more potent at inhibiting action potentials that ride on a depolarized plateau potential as characteristically occurs in seizures. Thus, sodium channel–blocking AEDs preferentially inhibit seizure discharges in relation to normal ongoing neural activity. By virtue of their ability to inhibit the action potential invasion of nerve terminals, sodium channel–blocking AEDs inhibit the release of diverse neurotransmitters including glutamate; whether this is responsible for the therapeutic activity of the drugs is uncertain (5).

The binding site on sodium channels for sodium channel–blocking AEDs is believed to overlap the binding site of local anesthetics, which is within the pore of the channel and is formed by the S6 segments of domains I, II, and IV. Sodium channel–blocking AEDs bind with higher affinity to this site when the channel is in the inactivated state, and, when such a drug is bound, the channel is stabilized in the inactivated state. When neurons are depolarized and firing rapidly, sodium channels spend a greater amount time in the inactivated state and are able to accumulate bound drug so that they become trapped in the inactivated state. This accounts for the use-and voltage-dependent blocking action that they exhibit. Phenytoin, carbamazepine, and lamotrigine are considered “classical” sodium channel–blocking AEDs. Lacosamide also is believed to exert its therapeutic effects by interacting with sodium channels (6). Unlike other sodium channel–blocking
### MOLECULAR TARGETS OF CLINICALLY USED AEDS

<table>
<thead>
<tr>
<th>Molecular target</th>
<th>AEDs that act on target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Voltage-gated ion channels</td>
<td></td>
</tr>
<tr>
<td>Voltage-gated sodium channels</td>
<td>Phenytoin, fosphenytoin, carbamazepine, oxcarbazepine, eslicarbazepine acetate, lamotrigine, and lacosamide; possibly, topiramate, zonisamide, and rufinamide</td>
</tr>
<tr>
<td>Voltage-gated calcium channels</td>
<td>Ethosuximide</td>
</tr>
<tr>
<td>Voltage-gated potassium channels</td>
<td>Ezogabine</td>
</tr>
<tr>
<td>GABA inhibition</td>
<td></td>
</tr>
<tr>
<td>GABA_A receptors</td>
<td>Phenobarbital, primidone, and benzodiazepines including diazepam, lorazepam, and clonazepam; possibly, topiramate and felbamate</td>
</tr>
<tr>
<td>GAT-1 GABA transporter</td>
<td>Tiagabine</td>
</tr>
<tr>
<td>GABA transaminase</td>
<td>Vigabatrin</td>
</tr>
<tr>
<td>Synaptic release machinery</td>
<td></td>
</tr>
<tr>
<td>SV2A</td>
<td>Levetiracetam</td>
</tr>
<tr>
<td>α2δ</td>
<td>Gabapentin, gabapentin enacarbil, and pregabalin</td>
</tr>
<tr>
<td>Ionotropic glutamate receptors</td>
<td></td>
</tr>
<tr>
<td>AMPA receptor</td>
<td>Perampanel</td>
</tr>
<tr>
<td>Mixed/unknown</td>
<td>Valproate, felbamate, topiramate, zonisamide, rufinamide, and adrenocorticotropic</td>
</tr>
</tbody>
</table>

- Fosphenytoin is a prodrug for phenytoin.
- Oxcarbazepine serves largely as a prodrug for carbamazepine, mainly 3-carbamazepine.
- Eslicarbazepine acetate is a prodrug for 3-carbamazepine.
- Gabapentin enacarbil is a prodrug for gabapentin.

AEDs, lacosamide does not inhibit high-frequency repetitive spike firing on the time scale of 100s of milliseconds. It does, however, inhibit spike firing in long trains of spikes on the time scale of 1 to 2 seconds. It has been proposed that the very slow action of lacosamide is due to an enhancement of a distinct and poorly understood form of inactivation, referred to as “slow inactivation.” However, an alternative explanation is that lacosamide binds more slowly to fast inactivated sodium channels than the other sodium channel-blocking AEDs. In any case, the unusually slow development of block produced by lacosamide during high-frequency activity could allow lacosamide to better discriminate between seizure-like pathologic firing and normal network activity.

### T-Type Voltage-Gated Calcium Channels

Low voltage-activated (T-type) calcium channels play a role in the intrinsic thalamocortical oscillations that underlie the spike-and-wave discharges of generalized absence seizures (7–9). There are three T-type Ca$\text{V}^{3.1}$ channel isoforms encoded by separate genes, denoted as Ca$_{V3.1}$ (α1G), Ca$_{V3.2}$ (α1H), and Ca$_{V3.3}$ (α1I). All three T-type calcium channel isoforms are expressed in thalamocortical circuits (10). Ca$_{V3.1}$ is prominently expressed in thalamic relay neurons in the dorsal thalamus, which plays a key role in absence seizures; Ca$_{V3.2}$ and to a lesser extent Ca$_{V3.3}$ are prominently expressed in thalamic reticular neurons. All three T-type calcium channel isoforms are expressed in the cortex, with Ca$_{V3.2}$ mainly localized to layer V. In non-REM sleep, including during delta waves, sleep spindles, and K complexes, the thalamocortical circuit switches from a tonic to oscillatory mode of firing, but in absence epilepsy, this switching can occur inappropriately, even during wakefulness (11,12). T-type calcium channels in the thalamus and cortex contribute to the abnormal behavior of the circuit. These channels generate low-threshold spikes, leading to burst firing and oscillatory behavior (13). GABA-ergic neurons of the thalamic reticular nucleus are also critically involved in absence seizures as they hyperpolarize thalamic relay neurons, which de-inactivates T-type calcium channels allowing the channels to generate burst firing and the propagation of spike-and-wave discharges in the thalamocortical circuit (14).

Ethosuximide, which is highly efficacious in the treatment of absence seizures but not other seizure types, seems to act by inhibition of T-type calcium channels in the thalamocortical circuit (15–17). At clinically relevant concentrations (20 to 40 μg/mL), some but not all investigators have observed a partial (20% to 30%) reduction of T-type calcium current by ethosuximide. However, studies with recombinant T-type calcium channels have confirmed that ethosuximide blocks all three channel types (18). The block increases when the current is activated from more depolarized potentials and when T-type calcium channels are inactivated as especially occurs during high-frequency activation, so that the drug has selectivity for pathologic behavior in the thalamocortical circuit, which is associated with neuronal depolarization and inactivation of T-type calcium channels. Effects on other membrane currents, including I_{NaP} and calcium-activated potassium current, may contribute to the efficacy of ethosuximide in absence epilepsy (17). Remarkably, results in animal models indicate that early treatment with ethosuximide can have disease-modifying (antiepileptogenic) effects, causing a persistent reduction in seizures and mitigation of behavioral comorbidities (19,20). These actions may be caused by epigenetic modifications. A study showing that children with absence epilepsy who

---

0002201396.INDD 2

11/19/2014 5:03:33 PM
receive ethosuximide are more likely than those who receive valproic acid to achieve long-term remission is consistent with the disease-modifying actions observed in animal studies (21).

The efficacy of some other AEDs may also depend, at least in part, on actions at T-type calcium channels. Zonisamide, in addition to effects on voltage-activated sodium channels, may also block T-type calcium channels (11), thus accounting for its likely efficacy in absence epilepsy (22). Similarly, there is evidence that valproate, a drug of choice in absence epilepsy, may also inhibit T-type calcium channels (17).

**Kv7 Voltage-Gated Potassium Channels**

Voltage-gated potassium channels are a diverse and evolutionarily ancient group of ion channels that serve a variety of key functions in the nervous system. Opening of potassium channels drives the membrane potential toward a hyperpolarized level, which serves to repolarize depolarizing events (such as action potentials and synaptic potentials) and cause a generalized reduction in excitability. In 1998, the first genes for a human idiopathic epilepsy were identified (23). These genes, designated KCNQ2 and KCNQ3, encoded novel brain potassium channel subunits, K7.2 and K7.3, respectively, that are homologous to a previously identified cardiac potassium channel K7.1, encoded by KCNQ1 (LQT1). The novel brain potassium channels mediate the M-current, a potassium current that increases as the membrane potential in neurons approach action potential threshold. K7 channels, together with HCN (hyperpolarization-activated cyclic nucleotide-gated potassium channels) and Ka2/SK (small-conductance calcium-activated potassium channels), generate the medium after hyperpolarization, which is elicited by a burst of action potentials and serves to limit further firing (24). K7 potassium channels therefore contribute to spike-frequency adaptation and can be considered to serve as a “brake” on epileptic firing. The K7 family of potassium channels is now known to contain five members, including K7.1, which is expressed predominantly in the heart, and K7.2 to K7.5, which are expressed exclusively in the nervous system (25).

Ezogabine, which is efficacious in the treatment of paroxysmal seizures, acts as a positive modulator of the nervous system K7 potassium channels (K7.2 to K7.5) but does not affect the cardiac member of the family (K7.1). Of particular relevance to the antiseizure action of ezogabine is its action on the M-current, which is predominantly carried by channels composed of K7.2 and K7.3, although K7.5 alone or in combination with K7.3 also contributes (26,27). Ezogabine causes a hyperpolarizing shift in the activation of K7 channels such that more M-current is generated near resting potential. It also causes a change in the kinetics of single KCNQ channels to favor channel opening, thus increasing the macroscopic M-current; ezogabine does not alter the single-channel conductance of individual K7 channels (28). Many K7 channels in the brain are believed to be K7.2/K7.3 heteromers, which are highly sensitive to ezogabine (EC50, 1.6 μM) (27). Peak plasma levels of ezogabine range from 354 to 717 ng/mL (1.2 to 2.4 μM) (29), and plasma protein binding is 80% so that free plasma concentrations are estimated to be about 0.2 to 0.5 μM; brain concentrations are expected to be similar. Therefore, therapeutic concentrations likely only modestly potentiate the most sensitive K7 channels and do not affect less sensitive channels. The binding site for ezogabine in K7.2/K7.3 heteromers is in a pocket formed by the pore-lining S5 membrane segment of one subunit and the pore-lining S6 membrane segment of the neighboring subunit (30,31). Channel opening may expose the pocket, permitting binding of ezogabine, which stabilizes the open-channel conformation.

**GABA Inhibition**

GABA, the neurotransmitter of local inhibitory interneurons, acts through GABA_A receptors and GABA_B receptors. GABA_A receptors, which are Cys loop-type ligand-gated chloride channels, represent an important target for AEDs and will be considered here; GABA_B receptors, which are heterodimeric G protein-coupled receptors that activate potassium channels and inhibit calcium channels, are distinct in structure and function from GABA_A receptors and are not a target of any AED. Although only about one in five cortical neurons is GABA-ergic (32), these neurons play a critical role in controlling the firing rate and timing of principal (excitatory) neurons. In addition, they synchronize local neuronal ensembles and restrain the generation of abnormal epileptic behavior. Consequently, enhancement of GABA-ergic inhibition is a key mechanism of AED action.

**GABA_A Receptors**

GABA_A receptors are heteropentameric protein complexes localized to the postsynaptic membrane of inhibitory synapses where they mediate fast neuronal inhibition on a millisecond time scale. They are also located extrasynaptically where they respond to ambient GABA in the extracellular milieu and confer tonic (long-term) inhibition. There are 19 known GABA_A receptor subunits (α1 to 6, β1 to 3, γ1 to 3, ε, δ, θ, π, and ρ1 to 3). However, the bulk (60%) of synaptic GABA_A receptors are believed to have the α1β2γ2 configuration, and a considerable fraction of the remainder (15% to 20%) are α2β3γ2. Among the receptor subtypes that contribute to tonic signaling in the brain regions relevant to epilepsy are α4β6δ8 receptors, which are believed to mediate the tonic current in dentate granule cells and thalamocortical neurons, and α5-containing GABA_A receptors in CA1 pyramidal cells (33).

Benzodiazepines, such as diazepam, lorazepam, and clonazepam, and barbiturates, such as phenobarbital, are AEDs that act on GABA_A receptors as positive allosteric modulators. At higher concentration, barbiturates can directly activate GABA_A receptors in the absence of GABA (34), whereas benzodiazepines cannot. Benzodiazepines are specific for synaptic GABA_A receptors containing the γ2 subunit and act to allosterically modulate these receptors to increase the channel opening frequency resulting in enhanced synaptic inhibition. This confers a broad-spectrum anticonvulsant action. In most epilepsy syndromes, the specific cellular types that are involved in the antiseizure activity of benzodiazepines are not known. However, in the case of absence epilepsy, it is believed that benzodiazepines desynchronize the thalamocortical oscillations underlying generalized spike-and-wave discharges by specific effects on α3-containing GABA_A receptors in the thalamic reticular nucleus (35). Barbiturates, presumably because they are not specific for α3-containing GABA_A receptors, are not active in absence epilepsy and may even aggravate absence seizures. In contrast to benzodiazepines, barbiturates do not appear
to increase the frequency of GABA-induced chloride channel opening, but instead increase the channel open time. In addition to effects on GABA receptors, barbiturates modulate other ion channel systems, including calcium and sodium channels, and these actions may contribute to therapeutic activity (36).

**GAT-1 GABA Transporter**

The action of neurotransmitter GABA is terminated by uptake into neurons and glial cell by membrane-bound GABA transporters, of which there are four types, termed GAT-1, BGT-1, GAT-2, and GAT-3. GAT-1 (encoded by the $SLC6A1$ gene), the predominant form in the forebrain (including the neocortex and hippocampus), is localized to GABA-ergic terminals as well as to glial processes near GABA synapses. Tiagabine is a highly selective inhibitor of GAT-1 in neurons and glia (37). Inhibition of GAT-1 by tiagabine suppresses the translocation of extracellular GABA into the intracellular compartment, thus raising extracellular GABA levels. Functionally, tiagabine prolongs GABA-mediated inhibitory synaptic responses, and the marked elevation in extracellular GABA it produces may lead to activation of extrasynaptic GABAA receptors.

**GABA Transaminase**

4-Aminobutyrate aminotransferase (GABA transaminase), an enzyme that catalyzes the conversion of GABA and 2-oxoglutarate into succinimide, is responsible for the metabolic inactivation of GABA. Inhibition of GABA transaminase with vigabatrin (γ-vinyl GABA), an irreversible suicide inhibitor of the enzyme, leads to marked increases in brain GABA levels. Although the antiseizure action of vigabatrin is believed to reflect inactivation of GABA transaminase, how this occurs is not straightforward and does not appear to be due to an enhancement of inhibitory synaptic transmission. In contrast to the action of tiagabine, vigabatrin does not elicit larger or more prolonged GABA<sub>Δ</sub> receptor-mediated synaptic responses (38,39). Rather, preincubation of brain slices with vigabatrin irreversibly inhibited miniature and evoked inhibitory postsynaptic currents. Additional experiments suggested that the paradoxical effect resulted from a reduction in the GABA content of synaptic vesicles caused by GABA transaminase inhibition. In contrast to the effect on GABA-mediated synaptic transmission, vigabatrin caused an increase in nonsynaptic tonic GABA<sub>Δ</sub> receptor current. This steady current is believed to be mediated by the action of GABA in the extracellular milieu acting on extrasynaptic GABA<sub>Δ</sub> receptors. High levels of intracellular GABA cause a reversal of GABA transporters, resulting in a marked elevation in extracellular GABA, which is likely responsible for the increase in tonic GABA<sub>Δ</sub> receptor current. It can be concluded that vigabatrin causes divergent effects on synaptic and extrasynaptic GABA-mediated inhibition, with seizure protection resulting from a predominance of the extrasynaptic action. Interestingly, in the early period after administration of vigabatrin to animals, there is a reduction in seizure threshold, whereas the anticonvulsant actions become evident only later (40,41). Thus, vigabatrin has a biphasic action with proconvulsant effects likely related to suppression of synaptic GABA-ergic neurotransmission and anticonvulsant effects due to spillover of GABA into the extracellular space and activation of extrasynaptic GABA<sub>Δ</sub> receptors.

Interestingly, individuals with a rare genetic deficiency of GABA transaminase experience refractory seizures, supporting the view that inhibition of GABA transaminase is in fact the proconvulsant mechanism of vigabatrin (42).

### SYNAPTIC RELEASE MACHINERY

**SV2A**

A variety of lines of evidence support the conclusion that SV2A, a membrane glycoprotein found in the secretory vesicles of neurons and endocrine cells and possibly immune cells, is the molecular target for levetiracetam (43,44). There is a strong correlation between the affinity of levetiracetam analogs for binding to SV2A and the potency of the analogs in several animal seizure models. Moreover, seizure protection conferred by levetiracetam and other SV2A ligands strongly correlates with the degree of SV2A occupancy in vivo. Finally, the anticonvulsant efficacy of levetiracetam but not valproate, which does not interact with SV2A, is reduced in SV2A<sup>−/−</sup> mice that have one copy of SV2A disrupted by gene targeting. The precise way in which binding of levetiracetam to SV2A leads to seizure protection is not understood.

Indeed, the function of SV2A itself is obscure. Among the various functions proposed are roles in calcium-dependent exocytosis, neurotransmitter loading/retention in synaptic vesicles, and synaptic vesicle priming, as well as transport of vesicle constituents. SV2A is one of three homologous of SV2 proteins that belong to the major facilitator superfamily of 12-transmembrane domain transporters. Despite substantial effort, no transport function of these proteins has been identified, although studies with protein tomography have found that SV2A can adopt two alternate conformations consistent with a transporter role (45). Interestingly, however, levetiracetam binding does not cause a large-scale conformational change in SV2A or lock a specific conformational state of the protein as would an inhibitor of transport. Apparently, the drug has a more subtle effect on the protein. Although the function of SV2A is still poorly defined, SV2A<sup>−/−</sup> knockout mice exhibit a lethal seizure phenotype demonstrating that SV2A in some way serves to restrain seizures.

A series of recent studies has examined the impact of levetiracetam on synaptic transmission in brain slice recordings (46). Although the drug had no effect on synaptic physiology with low-frequency activation, levetiracetam did reduce the synaptic release of both excitatory (glutamate) and inhibitory (GABA) neurotransmitters during high-frequency activation. The frequency dependence is compatible with the selective suppression of epileptic activity. Modulation of synaptic release is a common mechanism of many AEDs, including sodium channel blockers that indirectly inhibit release at both excitatory and inhibitory synapses by inhibiting action potential firing. It seems that drugs that suppress inhibition and excitation can effectively protect against seizures and they are not often proconvulsant. However, it is noteworthy that in some instances AEDs (notably phenytoin) can have proconvulsant effects.

**α2δ-1**

The gabapentinoid gabapentin and pregabalin act by binding to the α2δ-1 protein, which is an accessory subunit of voltage-gated calcium channels (47,48). α2δ-1 is located...
heterogeneously in the brain, particularly at presynaptic sites on excitatory (glutamatergic) neurons. Dense expression is observed in areas relevant to epilepsy, including in excitatory hippocampal mossy fibers and in the neocortex and amygdala. In contrast, α2β-1 has minimal expression in the thalamus, and it is noteworthy that gabapentinoids are not active in absence seizures, which as discussed above are dependent upon this brain structure. Four α2β subunits have been identified, but gabapentinoids only bind to α2δ-1 and α2δ-2 owing to the presence of a RRR motif containing a critical arginine that is required for binding. Seizure protection conferred by gabapentinoids is eliminated in mice bearing a mutation in this motif (RRR mutated to RRA) in α2δ-1, demonstrating that α2δ-1 and not α2δ-2 is relevant for pharmacologic activity. Interestingly, deletion of α2δ-1 or α2δ-2 in mice is associated with absence epilepsy or enhanced seizure susceptibility (49,50).

The precise way in which binding of gabapentin and pregabalin to the α2δ-1 protein confers seizure protection is not well understood (51). Although some studies have found that the drugs inhibit calcium channel currents, most have not and it is generally believed that calcium channel inhibition is not the mechanism of action of gabapentinoids (52–54). Regardless of whether the drugs inhibit calcium channel function, they do seem to block the release of various neurotransmitters, including glutamate, and this may account for the antiseizure activity (55). There is some evidence that gabapentinoids cause internalization of calcium channels by reducing trafficking to the cell membrane (56,57). Whether this action could account for the rapid anti-seizure effects of gabapentinoids in animal models is uncertain.

AMPA RECEPTORS

Perampanel is the first selective AMPA receptor antagonist approved for epilepsy treatment. Whereas GABA_A receptors mediate fast synaptic inhibition, AMPA receptors are cation channels that serve as the main mediators of fast (millisecond time scale) synaptic excitation. It has been long appreciated that cascading excitation within networks of synaptically connected neurons is a key mechanism of epileptic synchronization, at least in the hippocampal CA3 region and possibly in other brain areas (58). Epileptic activity emerges from the network when GABA-mediated inhibition is deficient, and indeed chronic alterations in inhibition represent a leading hypothesis to explain some forms of epilepsy.

Fast synaptic excitation is elicited by the exocytotic release of glutamate from excitatory principal neurons, which diffuses across the synaptic cleft and interacts with ionotropic glutamate receptors (iGluRs) of the AMPA and NMDA types to generate excitatory postsynaptic potentials (EPSPs). Summation of EPSPs leads to the firing of action potentials by the postsynaptic neuron. AMPA receptors have a special role in epileptic activity as epileptic synchronization cannot occur when AMPA receptors are blocked. In contrast, kainate receptors, which are iGluRs that have a similar structure to AMPA receptors, do not have a similarly essential role as kainate receptor knockout does not interfere with seizure generation (59). NMDA receptors are thought to contribute to epileptiform activity, but the blockade of NMDA receptors is insufficient to abolish epileptiform discharges in many seizure models (60). Pharmacologic blockade of AMPA receptors has broad-spectrum anticonvulsant activity in in vitro and animal seizure models.

Perampanel is a potent noncompetitive antagonist of AMPA receptors that does not affect NMDA receptor responses and has no known effects on other ion channels or molecular targets at therapeutically relevant concentrations (61). Therapeutic blood levels are expected to result in brain concentrations that would produce only low levels of inhibition of AMPA receptors. However, such low-level block of AMPA receptors is apparently sufficient to exert a clinical antiseizure action. Perampanel has a relatively low therapeutic window. Adverse central nervous system effects such as dizziness, irritability, and somnolence are common, particularly at higher-dose levels, emphasizing the importance of AMPA receptors in brain function.

MIXED/UNKNOWN ACTIONS

Valproate

Although valproate is one of the most valuable AEDs, the mechanism by which it protects against seizures is poorly understood. Valproate has multiple pharmacologic actions (62,63). Since it has been difficult to relate any one mechanism to the drug’s broad spectrum of activity, it has been proposed that combined actions on several targets could account for its therapeutic properties. Although the actions of valproate on GABA systems are not straightforward, among the various pharmacologic effects that have been described, those related to GABA mechanisms are among the most likely to be relevant to valproate’s antiseizure activity. For example, valproate increases the turnover of GABA, and this might be associated with enhanced synaptic or extrasynaptic inhibition. At high concentrations, valproate affects voltage-gated sodium channels, but recent studies in brain slice recordings have failed to provide support for sodium channel block as a relevant mechanism to explain clinical activity (64). Similarly, despite efficacy in absence epilepsy, there is little support for effects on T-type calcium channels. It is likely that valproate has pharmacologic actions relevant to its antiseizure activity that remain to be elucidated.

Felbamate

Felbamate, at concentrations within the therapeutic range, has been shown both to act as positive modulators of GABA_A receptors and also to inhibit NMDA receptors (65). Felbamate potentiates GABA responses via an interaction with a site on the GABA_A receptor that is distinct from the benzodiazepine recognition site. This action may be of relevance to felbamate’s clinical activity. Although drugs that block NMDA receptors can exert antiseizure effects in certain animal models, there is doubt whether blockade of NMDA receptors is a useful strategy to treat epilepsy (66). Therefore, it is uncertain whether the NMDA receptor–blocking activity of felbamate is relevant to its clinical antiseizure activity.

Topiramate

As is the case for valproate and felbamate, the broad-spectrum anticonvulsant activity of topiramate is likely to result from mixed effects on several targets (67). Among topiramate’s diverse pharmacologic actions, effects on voltage-activated
sodium channels, GABA<sub>A</sub> receptor subtypes, AMPA or kainate receptors, and types II and IV carbonic anhydrase isoenzymes are potentially relevant to seizure protection. Unlike other AEDs, the effects on ion channels are unlikely to occur through direct modulation of channel gating. Rather, the pharmacologic actions of topiramate seem to be mediated indirectly, possibly through effects on channel phosphorylation.

The effects of topiramate on sodium channels occur at relatively low, therapeutically relevant concentrations and could be similar to the effects of other sodium channel-blocking AEDs (68). In addition to effects on fast sodium currents, topiramate, like phenytoin, blocks I<sub>NaP</sub> at low concentrations. Effects of topiramate on GABA<sub>A</sub> receptors could contribute to the broad spectrum of activity of topiramate. Topiramate is not active in animal models, such as the pentyleneetrazol test, that are typically sensitive to drugs that positively modulate GABA<sub>A</sub> receptors. Nevertheless, the drug does have activity in an absence epilepsy model and can affect pentyleneetrazol threshold, which is consistent with effects on GABA<sub>A</sub> receptors. There is evidence that topiramate may preferentially modulate a subset of GABA<sub>A</sub> receptors and that drug sensitivity is dependent upon the β-subunit type (69).

Several authors have suggested that actions on fast glutamate-mediated excitatory neurotransmission could contribute to topiramate's antiepileptic activity. In cultured neurons, the drug has been reported to inhibit responses to kainate, an agonist of AMPA and kainate receptors, leading to the conclusion that topiramate could be an antagonist of either AMPA or kainate receptors (70). Recently, kainate receptors have been found to be an unlikely target for an antiseizure agent (71). Whether actions of topiramate on glutamate-mediated neurotransmission contribute to its anticonvulsant activity remains to be determined.

The action of topiramate on carbonic anhydrase has been assumed not to contribute to its clinical efficacy because there is no cross-tolerance to the anticonvulsant activity of topiramate when tolerance occurs to the classical carbonic anhydrase inhibitor acetazolamide in mice. However, a recent review left open the possibility that carbonic anhydrase inhibition could, in part, play a role (67).

Zonisamide

There are some similarities between topiramate and zonisamide as they both contain a sulfur atom and both inhibit carbonic anhydrase. In addition, like topiramate, zonisamide may act on voltage-dependent sodium channels (72). Physiologic studies do not support an action on GABA<sub>A</sub> receptors. Unlike topiramate, there are reports that zonisamide can inhibit T-type voltage-gated calcium channels (73), which may account for its activity in absence epilepsy.

Rufinamide

The unique spectrum of clinical activity of rufinamide in the treatment of the Lennox–Gastaut syndrome suggests that it has a distinct mechanism of action (26). However, to date, rufinamide has only been shown to interact with voltage-gated sodium channels, and the effects are subtle. Relevant concentrations of the drug may, at least for some subunit isoforms, cause a depolarization in the activation voltage and slowing of recovery from inactivation, which would be expected to reduce neuronal excitability (74). Clearly, the effects on sodium channels cannot explain the special clinical activity of rufinamide.

Adrenocorticotropic hormone

The mechanism of adrenocorticotropic hormone (ACTH) in the treatment of infantile spasms is not understood (75). ACTH stimulates glucocorticoid (cortisol) synthesis and release from the zona fasciculata of the adrenal cortex. The cortisol could produce an antiinflammatory action or have some other action in the brain to influence infantile spasms. Indeed, glucocorticoids are well recognized to themselves have therapeutic activity in the treatment of infantile spasms; whether ACTH is truly superior remains to be demonstrated conclusively. One possible additional action of ACTH that could contribute to enhanced activity is stimulation of neurosteroid synthesis. In addition to its actions with respect to glucocorticoids, ACTH also stimulates deoxycorticosterone (DOC) release from the zona glomerulosa of the adrenal cortex. DOC is, in part, converted to the anticonvulsant neurosteroid tetrahydro-DOC, which is a positive allosteric modulator of GABA<sub>A</sub> receptors (76). It has been hypothesized that the tetrahydro-DOC could, at least in part, contribute to the ability of ACTH to terminate infantile spasms.

BASIS OF COMBINATIONAL TREATMENT

All clinically used AEDs protect against seizures in animal models as single agents. Studies with early AEDs suggested that the seizure protection conferred by drug combinations is simply additive (77). Since the use of more than one agent compounds the risk of side effects, these and other observations led to the recommendation that AEDs should be tried sequentially in monotherapy before combining agents. More recent experimental data suggest that combining drugs with complementary mechanisms of action might lead to synergism for efficacy (78). Observational studies of results obtained in clinical practice have shown that combining newer AEDs with different mechanisms of action may have greater effectiveness (a combination of efficacy and tolerability) than combining drugs with similar mechanisms of action (79). Consequently, an understanding of mechanism may impact clinical decision making in regard to the choice of drug combinations.

References

Chapter 43: Mechanisms of Action of Antiepileptic Drugs


8. Huguenard JR. Block of T-type Ca2+ channels is an important action of succinimide antiepileptic drugs. Epilepsy Curr. 2002;2(2):49–52.


42. Neuman R, Cherubini E, Ben-Ari Y. EPILEPTOFORM BURSTS ELCITED IN CA3 hippocampal neurons by a variety of convulsants are not blocked by α-Methyl-D-aspartate antagonists. Brain Res. 1988;459(2):265–274.


Part IV: Antiepileptic Medications